Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: axial who wrote (13706)	10/6/2004 10:30:32 PM
From: russet	Read Replies (1) \| Respond to of 14101

Contrary to the posts we've been reading here, the requirement for more trials is likely to have a cause we've ALL missed. Despite the megalomanic posturing, it's not what our fave potato thinks. FDA approval of the P2 for Penecure virtually guarantees that. FDA approval for studies of Penecure guarantees nothing. Your normal response,...your ego stops you from admitting I was right. Who is the real obfuscator, the real charlatan? You and your cult including your favorite doctors,..and you all got the haircut you deserved by not doing the proper DD. FDA says they want real data proving how Pennsaid works, and long term safety and efficacy studies. Russet is vindicated 100%

To: axial who wrote (13706)	10/6/2004 10:43:51 PM
From: SofaSpud	Read Replies (1) \| Respond to of 14101

Am I missing something, or does this mean no U.S. Pennsaid sales for the next three years? And just when does the patent expire? Barring unforeseen delays, we expect to complete the studies by the end of calendar 2005 and submit an amended NDA by mid 2006. According to agency guidelines, the FDA should be expected to respond by early 2007. A positive response at this stage would allow the company to begin marketing Pennsaid three-to-six months later.